SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), the leading destination for prescription savings, today shared a report looking at the company’s impact on social welfare as a result of helping millions of people access affordable medications. “The GoodRx Effect: How GoodRx is Changing the Economics of Healthcare” shows that by saving people money and improving medication adherence, GoodRx positively impacts health outcomes and significantly reduces costs within the healthcare system – includin ...

GoodRx Holdings, Inc. (GDRX) shares rallied 13.3% in the last trading session to close at $6.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.2% loss over the past four weeks.GoodRx scored a strong price increase, on investors’ optimism driven by the company’s announcement of preliminary financial results for the fourth quarter and fiscal year ended Dec 31, 2023. The company’s fourth quarter revenues are ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings, today provided preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Revenue1,2 and Adjusted Revenue1,2 expected to be in the range of $195 million to $197 million Adjusted EBITDA Margin2,3 expected to be in the upper end of previous guidance range provided on November 9, 2023 ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board’s audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessment manageme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 _____________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 _________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5104396 (State or o ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Representatives Doug Hirsch - Co-Founders, Co-Chief Executive Officer Trevor Bezdek - Co-Founders, Co-Chief Executive Officer Karsten Voermann - Chief Financial Officer Aubrey Reynolds - Senior Investor Relations Manager Conference Call Participants Mark Mahaney - Evercore ISI Mitchell Kellett - Guggenheim Lucas Romanski - Cowen Michael Cherny - Bank of America Craig Hettenbach - Morgan Stanley Eric She ...

Revenue and Financial Performance - Revenue for the year ended December 31, 2022, grew 3% to $766.6 million from $745.4 million in 2021[304] - Net loss for 2022 was $32.8 million, with a net loss margin of 4.3%, compared to a net loss of $25.3 million and a margin of 3.4% in 2021[304] - Adjusted EBITDA for 2022 was $213.5 million, with an Adjusted EBITDA Margin of 27.8%, down from $229.6 million and 30.8% in 2021[304] - The estimated impact of the "grocer issue" on prescription transactions revenue in 2022 was approximately $110.0 million to $120.0 million[302] - Prescription transactions revenue decreased by $42.8 million, or 7%, year-over-year, primarily due to a 2% decrease in average Monthly Active Consumers[323] Consumer Metrics - Monthly Active Consumers for December 2022 were reported at 5.9 million, reflecting a decline due to the grocer issue[309] - Subscription plans as of December 31, 2022, totaled 1,030,000, down from 1,210,000 in December 2021[311] - The company expects continued adverse impacts on prescription transactions revenue and Monthly Active Consumers due to ongoing consumer response uncertainties[302] Revenue Streams - Pharma manufacturer solutions revenue is expected to grow as a percentage of total revenue in the near to medium term[318] - Pharma manufacturer solutions revenue increased by $26.1 million, or 36%, year-over-year, driven by organic growth and the acquisition of vitaCare, contributing $5.6 million in 2022[324] - Subscription revenue increased by $36.2 million, or 60%, year-over-year, despite a 15% decrease in the number of subscription plans to 1,030 thousand[325] Costs and Expenses - Cost of revenue increased by $18.4 million, or 39%, year-over-year, primarily due to increased personnel costs and fulfillment costs related to the vitaCare acquisition[328] - Product development and technology expenses increased by $17.3 million, or 14%, year-over-year, driven by higher payroll costs due to increased headcount[329] - Sales and marketing expenses decreased by $12.6 million, or 3%, year-over-year, primarily due to a $69.9 million decrease in advertising expenses[330] - General and administrative expenses decreased by $9.9 million, or 6%, year-over-year, mainly due to a decrease in stock-based compensation expense[331] - Depreciation and amortization expenses increased by $19.6 million, or 57%, year-over-year, primarily due to higher capitalized software amortization[332] Cash Flow and Investments - GoodRx Holdings, Inc. reported a net cash provided by operating activities of $146.78 million for the year ended December 31, 2022, a decrease of $32.0 million compared to $178.78 million in 2021[341] - The net cash used in investing activities increased by $31.8 million in 2022, totaling $210.50 million, primarily due to a $27.6 million increase in cash paid for acquisitions and a $21.4 million increase in software development costs[343] - Net cash used in financing activities rose by $89.7 million in 2022, amounting to $120.23 million, largely driven by $101.7 million for repurchases of Class A common stock[344] - The company reported a net cash change of $(183.94) million in cash, cash equivalents, and restricted cash for 2022, compared to $(30.48) million in 2021[341] Interest and Taxation - Interest income increased by $9.2 million year-over-year, primarily due to higher interest rates on cash equivalents[333] - As of December 31, 2022, GoodRx Holdings, Inc. maintained a full valuation allowance of $57.1 million against its net deferred tax assets in excess of amortizable goodwill[359] - A hypothetical 100 basis point increase in interest rates would have increased GoodRx's interest expense by $6.8 million for the year ended December 31, 2022[363] Economic Conditions - GoodRx Holdings, Inc. does not believe inflation has had a material effect on its business, but acknowledges potential risks if costs become subject to significant inflationary pressures[364]